Sanofi's Sotagliflozin: Risk Of Ketoacidosis Divides US FDA Advisory Committee
Executive Summary
Some Endocrinologic and Metabolic Drugs Advisory Committee members said a REMS is sufficient, but others worried that proposed risk management plans were not proven effective.
You may also be interested in...
With $260m Settlement From Sanofi, Lexicon Looks For New Zynquista Partner
Sanofi terminated its alliance for the SGLT1/2 inhibitor Zynquista, giving Lexicon full control of development in type 1 and type 2 diabetes, but it is seeking a new partner ideally with a European footprint.
Sanofi And Lexicon Fall Out Over Zynquista, As French Group Exits Diabetes Pact
Lexicon labelled Sanofi’s unilateral decision to exit their alliance ‘invalid’ and said the French drugmaker was thus ‘in breach of contract’. Sanofi said its move was triggered by Phase III trial data studying the dual SGLT1 and SGLT2 inhibitor in type-2 diabetes.
Keeping Track: Recarbrio Approval Highlights Two-Week Roundup
The latest drug development news and highlights for our US FDA Performance Tracker.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: